Introduction
Seminal studies by Saarni and Linman 1 began the recognition of a pre-leukemia characterized by qualitative abnormalities in more than one lineage and culminating in a monocytoid leukemic transformation. Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy characterized by myeloproliferative or myelodysplastic (MDS) features. Accordingly, the new World Health Organization classification classifies CMML in the MDS/myeloproliferative (MPD) neoplasm overlap category. 2 On the basis of more than 1000/mL of peripheral blood monocytes and peripheral and medullary blast count, CMML is subdivided into two subsets: CMML type 1 (CMML-1) with less than 10% medullary and less than 5% peripheral blasts, and CMML type 2 (CMML-2) with 10-19% medullary and 5-19% peripheral blasts. 2 Prognostic models that were developed specifically for CMML include the modified Bournemouth score, the MD Anderson Prognostic Score and the Spanish score. BM blasts, peripheral monocytosis, lymphocytosis and anemia are the covariates that are most associated with overall survival. [3] [4] [5] On the basis of the data of 339 patients with CMML, the Du¨sseldorf group showed that the prognosis of the two CMML subtypes as proposed by the WHO classification for MDS is different in terms of both survival and AML evolution. The median survival of patients with CMML-1 was 20 months, compared with 15 months for patients with CMML-2. The risk of developing overt AML was significantly greater for patients with CMML-2 compared with patients with CMML-1. 6 Therefore, the WHO classification distinction between CMML-1 and CMML-2 based on the medullary blast counts has significant prognostic value and may help in selecting appropriate treatment.
Clonal cytogenetic abnormalities are found in approximately 30% of patients with CMML, but none is specific. 7 The molecular background of CMML is poorly understood. Thus far, RAS pathway mutations (KRAS and NRAS), RUNX1 alterations, JAK2V617F point mutations, CBL, MPL mutations and TET2 alterations have been described. [8] [9] [10] [11] Kohlmann et al. 12 recently showed a characteristic pattern of molecular mutations in 72.8% of patients with CMML. In particular, TET2, CBL and RAS pathway alterations were detected, leading to a more precise molecular classification in CMML. TET2 was the most frequently mutated gene observed in 44.4% of CMML patients. A better outcome was seen for patients who carried TET2 mutations compared with patients with TET2 wild type (median overall survival, 130.4 vs 53.6 months, respectively; alive at 2 years, 81.2% vs 58.9%, respectively).
The treatment criteria for CMML patients are not strictly defined. Most patients are treated in the case of disease progression leading to high WBCs, cytopenias, splenomegaly or progression to AML. The comparison of treatment modalities is intricate because very few rando-mized studies are available and significant differences in treatment outcomes in older series probably reflect differences in risk scores that were applied then. 13 Hydroxyurea and oral etoposide are often used with response rates of 70%.
14 Topoisomerase-1 inhibitors combined with chemotherapy yield short duration responses for a rather toxic approach in CMML. 15, 16 A multicenter phase 2 study suggested a promising activity for tipifarnib, a farnesyl transferase inhibitor, which inhibits an important enzymatic process and in turn activates the RAS protein in CMML and other high-risk MDS subtypes. 17 Aberrant methylation of the important cell cycle regulatory gene p15(INK4b) with reduced protein expression was recently demonstrated in CMML, indicating that an epigenetic approach in the treatment of CMML might be justified. 18 Wijermans et al. 19 reported on the experience of four MDS studies in which CMML patients were included. Patients were entered in these trials because of progressive disease leading to cytopenias and an increase in blast cells. An overall response rate (CR þ PR) of 25% was observed with an additional 19% of the patients having a hematological improvement and 32% had stable disease. The survival seen in this small patient cohort seems not to differ from the large Du¨sseldorf series. 6 However, survival was measured from starting therapy and not from diagnosis and the patients had a higher risk disease requiring intervention. In other studies with the azanucleosides, decitabine and azacitidine, small numbers of CMML patients were included and responses were observed. [20] [21] [22] Non-randomized studies suggest that long-term remissions are achievable when using HCT as treatment for CMML. We therefore performed a literature search and reviewed available studies for hematopoietic stem cell transplantation (HST) in adult patients with CMML.
Methods
Literature search and study selection We searched the Medline (PubMed) electronic database by using a broad search strategy. The studies were identified by utilizing a combination of MeSH terms, such as 'CMML', 'MDS' and 'allogeneic transplantation'. Two reviewers (HC and VK) independently screened the list of references to assess their eligibility for inclusion in consultation with another reviewer (UG).
Inclusion criteria
Studies/patients meeting all of the following criteria were included in the review: (1) patient's age 418 years old; (2) first transplantation; and (3) availability of detailed patient's characteristics and outcome data such as relapsefree survival (RFS), OS, relapse rates (RR), and nonrelapse mortality.
Results

Identification of studies/patients
The process of identifying and selecting studies/patients for the review is outlined in Figure 1 . The initial search yielded 73 citations. In all, 18 references were selected for full-text analysis. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Two studies were exempt from the age limit inclusion criterion owing to their relative large size and the detailed analysis that was provided by the authors. Kerbauy et al. 28 reported on the transplant outcomes of 43 CMML patients age 1-66 years and, more recently, Eissa et al. 41 included this same cohort in an updated study of 85 patients with CMML who underwent HST at the Fred Hutchinson Cancer and Research Center. For the purpose of this review, we will include both studies in the list of selected studies, but we will only use the outcome analysis provided in the more recent paper.
In all, 197 patients from eight studies met the final inclusion criteria and were included in the review. All the included studies were published in full text. Characteristics of the studies/patients are summarized in Table 1 . 26, 28, 29, 31, 32, 34, 36, 40 All studies that fulfilled the inclusion criteria were retrospective studies, with six out of eight (71%) being single institution experiences. Two studies included patients with MDS or MPD, and provided details describing the outcome of adult CMML patients. 32, 34 Two studies included patients with CMML transforming to AML. 26, 29 The largest multicenter study comprising 50 adult patients with CMML was led by Kroger et al. 31 on behalf of European Group for Blood and Marrow Transplant.
Patient's characteristics. Patient characteristics are listed in Table 2 . The median age for eligible patients was 44-58 years (range 1-69 years). The median time from diagnosis to transplantation was mostly 7-10 months with three exceptions: the median interval was 21 months in the paper by Krishnamurthy et al. 29 and it was not available in two Excluded studies
• Included patients <18 yrs old and no details on patients >18 yrs except 2 studies by Kerbauy et al. 28 and Eissa et al. 40 • No details on the outcomes for CMML patients.
• Reviews Studies included in the final review Allogeneic HST for chronic myelomonocytic leukemia H Cheng et al studies by Mittal et al. 34 and Eissa et al. 40 Krishnamurthy et al. 29 further reported that the median time from diagnosis to transplantation was 17 months in survivors and was 25 months in patients who did not survive.
The patients were reported to undergo HST for CMML between 1988 and 2008. In particular, the more recently published four studies reported transplantations mostly between 1998 and 2008, 29, 32, 36, 40 whereas the four earlier studies included transplantations between 1988 and 2004. 26, 29, 31, 34 Disease burden at transplant. In all, 100 patients had BM blasts p5%, whereas 56 patients had BM blasts 45% at the time of transplantation. Blast percentage was not specified in the studies by Laport et al. 32 and Mittal et al. 34 Elliott et al. 26 reported a median BM blast of 6% (1-58%), but with no further details.
Cytogenetics. Cytogenetic risk as determined by the MDS International Prognostic Scoring System was available for 163 out of 197 patients. Of these, 89 patients had normal/ good risk, whereas 74 patients had abnormal/intermediate/ poor risk karyotype.
Conditioning. Reduced intensity conditioning (RIC) was utilized in 62 patients. Eighty-two percent of RIC transplants were conducted in the more recent studies. 29, 32, 36, 40 Myeloablative (MA) conditioning was utilized in 135 transplantations.
Graft source. In all, 111 patients had matched related donors and 72 patients had matched unrelated donors. Of these, 15 patients received mismatched related and unrelated adult stem cell grafts. Relatively, more matched 
Ocheni et al. 36 Hamburg unrelated donors were utilized in recent vs earlier transplantation studies. PBSCs were utilized in 97 patients, whereas stem cells harvested from BM were the graft source for 90 patients. Three patients received stem cells from both PBSCs and BM. The source of stem cells was not specified by Laport et al. 32 for patients with CMML, although overall 144 out of 148 patients had PBSCs.
Outcomes Three studies accounting for 32 patients reported on 3-year outcomes. However, the remaining five studies accounting for 160 patients had varied reported outcomes at different times (one study with 10 years, one study with 2 years, one study with 4 years, one study with 5 years and one study with 3 years, but stratified by blast). Accordingly, none of these studies can be compared directly with each other.
Overall survival. As shown is Table 1 , the OS at 2-10 years ranged from 18 to 75% for all studies. The four earlier studies had an OS of 18-37.5%, 26, 28, 31, 34 whereas the OS for the more recent studies is 31-75%. 29, 32, 36, 40 Relapse-free survival. The RFS (2-10 years) ranged from 18 to 67% for all included studies (Table 1 ). For the four earlier studies, 26, 28, 31, 34 the RFS was 18-41%, whereas for the more recent studies, the RFS was 43-67% for two of four studies. The study by Krishnamurthy et al. 29 did not report on overall RFS; instead, RFS was specified based on disease burden with a 3-year RFS of 47% in patients who had o5% BM blasts at the time of transplantation vs 20% in patients who had 45% BM blasts (P ¼ 0.33). Eissa et al. 40 did not report separately on the outcome of the more recent cohort. Instead, they estimated RFS for the entire 85 patients as being 40% at 10 years. Kerbauy et al. 28 estimated the 4-year RFS for the earlier 43 patients as being 41% at 4 years. Of note, children were included in both the earlier and the added more recent cohorts in this single institution experience. Thus, there is a tendency for improved RFS in adult CMML patients who underwent transplantation more recently.
Relapse rate. The RR at 2-4 years ranged from 17 to 62.5% for all patients. Earlier studies reported an RR of 25-62.5, 26, 28, 31, 34 while more recent reports had an RR of 25-57%. 29, 32, 36, 40 GVHD. In a chronological order starting from the most recently published study, the incidence of acute GVHD was 72, 44, 77, 75, 25 and 59% in studies by Eissa et al., 40 Krishnamurthy et al., 29 Ocheni et al., 36 Elliot et al., 26 Mittal et al. 34 and Kroger et al., 31 respectively. Similarly, the incidence of chronic GVHD was 44%, 17%, 50%, 40%, 37.5% and 26%, respectively. Laport et al. 32 did not specify the incidence of GVHD for their patients with CMML.
Discussion
There is a paucity of studies reported for HST in adult CMML patients. No prospective trials have been reported to date. All studies deemed eligible for this review were retrospective trials. Eissa et al. 40 reported on the largest series of CMML patients in a single institution, with 85 patients undergoing HST from 1986 to 2008. The study included children who usually fare better with more intensive treatment, did not specify their percentage in the total cohort and did not separate their outcome. However, increased age was clearly associated with increased mortality and RFS. The study published in 2002 by Kroger et al., 31 on behalf of the European Group for Blood and Marrow Transplant, remains to be the largest multicenter adult series so far, with 50 adult CMML patients undergoing SCT from 1988 to 2000.
On the basis of the limited and heterogeneous available data that does not allow for drawing definite conclusions, the year of transplantation appears to be an indirect predictive factor for outcomes. There is a tendency for improved 2-3 year RFS and 2-5 year OS for the more recent studies, in comparison to earlier studies. Interestingly, RR did not change over the past two decades and remains consistently high at 25-50%. Thus, the improved RFS seems to be a function of decreased TRM. The underlying mechanisms for this tendency are likely multifactorial, such as improved HLA matching techniques, the introduction of RIC and better supportive care. Allogeneic HST for chronic myelomonocytic leukemia H Cheng et al
Disease burden
Krishnamurthy et al. 29 reported a tendency for improved 3-year RFS based on disease burden, 47% in patients who had p5% BM blasts at the time of transplant vs 20% in patients who had 45% BM blasts (P ¼ 0.33). Kroger et al. 31 also noted a similar tendency with a lower blast count associated with lower RR and better 2-year RFS (33% for patients who had o10% marrow blasts before transplantation vs 12% if blasts were 410% (P ¼ 0.15). Eissa et al. 41 found MD Anderson Prognostic Score to be statistically significantly associated with higher RR (hazard ratio (HR) 1.65, P ¼ 0.01), but not long-term survival or RFS. Of note, BM blast percentage is a covariant of the MD Anderson Prognostic Score along with circulating immature cells, lymphocyte counts and hemoglobin levels.
GVHD
Kroger et al. 31 reported a tendency for lower RR in patients with acute GVHD grade II-IV (24% vs 54%, P ¼ 0.07). In addition, they noted that acute GVHD tended to associate with an improved 2-year RFS (28% vs 11%, P ¼ 0.11). 31 Laport et al. 32 also observed a tendency towards lower risk of relapse when patients developed extensive chronic GVHD for their entire cohort of seven adult CMML patients.
Karyotype
In multivariant analysis, Eissa et al. 40 found poor risk cytogenetics, as determined by the International Prognostic Scoring System, to be statistically significantly correlated with mortality/relapse (HR 3.35, P ¼ 0.0003), non-relapse mortality (HR 3.09, P ¼ 0.02) and overall mortality (HR 2.73, P ¼ 0.004). Krishnamurthy et al. 29 noted that none of the patients (n ¼ 7) with intermediate or poor risk cytogenetics, as determined by the International Prognostic Scoring System, survived by 2 years; instead, the patients with favorable cytogenetics had a 3-year RFS of 65%. Kroger et al. 31 reported that when compared with normal cytogenetics, complex cytogenetics or monosomy 7 tended to decrease OS (30% vs 18%) and RFS (26% vs 18%).
Conditioning intensity
The outcome of 27 patients who had an RIC HST in the Fred Hutchinson Cancer and Research Center series was not statistically significantly different than the 58 patients who had a MA transplant. However, the authors noted that the patients who were conditioned with fludarabine and targeted busulfan (RIC) had a lower relapse incidence and higher probability of survival. In addition, the 25% RR in the small cohort of patients who had nonmyeloablative transplant (six patients) was not statistically different from the RR observed in higher intensity regimens. 40 Krishnamurthy et al. 29 observed no significant impact of conditioning intensity on overall outcomes. Ocheni et al. 36 also reported that RIC did not appear to be correlated with worsening RR. It remains undefined whether RIC improves overall outcomes for HST in adult CMML patients. However, RIC helped expand the transplant option for patients who otherwise are not candidates for standard ablative conditioning owing to advanced age or coexisting co-morbidities.
Graft source
Eissa et al. 40 found no significant relationship between the source of stem cells or type of donor and OS or RFS. Of note, in this series, 12 patients received mismatched grafts from related (4) or unrelated (8) donors. Interestingly, female-to-female transplants were associated with a higher probability of relapse compared with male-to-male transplants in univariate analysis (HR 4.64, P ¼ 0.03). Lacking biological explanation for this association, the authors suggested that it is a result of multiple comparisons and may not be true. 40 Kroger et al. 31 reported that the type of donor (matched unrelated donor vs matched related donor) or utilization of PBSCs vs BM had no significant impact on RFS. They also noticed a higher RR in patients with T-cell-depleted grafts (62% vs 45%), suggesting a 'graft-vs-CMML effect.
Conclusion
Patients with CMML have an average life expectancy of 19 months. Allogeneic transplantation is a potentially curative option for a carefully selected group of patients. The hypomethylating agents achieved responses in up to 45% of CMML patients and were well tolerated on an ambulatory basis. However, their place in treatment algorithms should be in conjunction with HST for transplant-candidate patients. The advent of lower intensity conditioning, high-resolution HLA typing and improved supportive care have resulted in a marked decrease in non-relapse mortality. However, RR remains disappointing.
We recognize the inherent limitations to this narrative review and our inability to construct a formal meta-analysis. The studies could not be adequately pooled owing to the heterogeneity of patient's characteristics and outcomes. However, our aim is to present the current transplant data and include transplant in the treatment algorithm for CMML patients. The two largest papers by Kroger et al. 31 and Eissa et al. 40 proved a curative potential of transplant for CMML. GVHD was associated with a survival advantage in some of the quoted papers, but we could not statistically prove that concept in this narrative review. We made an exception and added the largest retrospective study by Eissa et al., 40 which included children:
1. Disease burden tended to directly affect RR and RFS. The use of hypomethylating agents before transplantation was well tolerated and did not appear to inversely affect post transplantation outcomes. The use of hypomethylating agents after transplant is an emerging concept that is currently being examined. It remains to be seen whether any of these strategies will have an impact on long-term transplant outcomes. 2. Acute GVHD was associated with improved RR and RFS in the largest adult retrospective trial by Kroger et al. 31 3. Poor risk cytogenetics increased RR and adversely affects RFS after HST for CMML patients. Incorporating a more modern molecular risk models as proposed by Kohlmann et al. 12 can aid transplant decisions in selected cases. 4 . RIC improved non-relapse mortality, OS and RFS without increasing RR, thus expanding this curative strategy to more CMML patients. 5. Graft source whether it is from BM or PBSC harvest or using a matched related or unrelated donors did not affect transplant outcomes. The small number of mismatched grafts (12 patients) does not allow for any meaningful comparison.
The decision to proceed with HST along with the timing of transplant in CMML disease course as well as choosing the conditioning regimen is a complex one. Pragmatically relevant disease parameters, molecular markers such as TET2 mutations as well as patient's parameters such as the co-morbidity index, age and performance status should help guide transplant decisions. 41 RIC appears to have similar outcomes compared with standard MA in adult CMML patients. The decision to choose MA vs RIC should be based on patient's factors in conjunction with disease burden at the time of transplant. There are insufficient data on the use of umbilical cord grafts when used as single, double cords or after ex vivo expansion. We recognize the limitation of our analysis, being a review of a limited number of retrospective studies spanning two decades of transplant experience in an otherwise recently reclassified rare hematological malignancy. The paucity of data, limited patient's number and heterogeneous transplant outcomes prohibited us from conducting a formal statistical analysis. However, to the best of our knowledge, this is the first attempt at addressing lessons learnt from applying a curative approach in CMML and could be the basis of future more rigorous clinical trials.
